NAMPT and familial pancreatic carcinoma: For instance, we demonstrated that NAPRT-expressing ovarian and pancreatic cancers are resistant to NAMPT inhibition, but downregulation of NAPRT significantly depletes intracellular NAD stores and sensitizes these tumors to NAMPT inhibitors [62].